These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7191149)

  • 1. Effect of hepatectomy on the posttraumatic fibrinolysis inhibition and the primary fibrinolysis inhibitor in the rat.
    Högstorp H; Jacobsson H; Saldeen T
    Thromb Res; 1980 May 1-15; 18(3-4):361-8. PubMed ID: 7191149
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanism of fibrin-specific fibrinolysis by staphylokinase: participation of alpha 2-plasmin inhibitor.
    Sakai M; Watanuki M; Matsuo O
    Biochem Biophys Res Commun; 1989 Jul; 162(2):830-7. PubMed ID: 2527034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha 2-antiplasmin causes thrombi to resist fibrinolysis induced by tissue plasminogen activator in experimental pulmonary embolism.
    Butte AN; Houng AK; Jang IK; Reed GL
    Circulation; 1997 Apr; 95(7):1886-91. PubMed ID: 9107177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the interaction between dextran and the primary fibrinolysis inhibitor alpha 2-antiplasmin.
    Carlin G; Saldeen T
    Thromb Res; 1980 Jul 1-15; 19(1-2):103-10. PubMed ID: 6160633
    [No Abstract]   [Full Text] [Related]  

  • 5. Alpha 2-antiplasmin supplementation inhibits tissue plasminogen activator-induced fibrinogenolysis and bleeding with little effect on thrombolysis.
    Weitz JI; Leslie B; Hirsh J; Klement P
    J Clin Invest; 1993 Apr; 91(4):1343-50. PubMed ID: 7682569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.
    Hare TR; Gardell SJ
    Thromb Haemost; 1992 Aug; 68(2):165-9. PubMed ID: 1412162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Molecular mechanisms of fibrinolysis and perspectives of thrombolytic therapy].
    Veremeenko KN; Kizim AI
    Vopr Med Khim; 1984; 30(5):13-22. PubMed ID: 6084892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Determination of fibrinolysis with peptide substrates].
    Teger-Nilsson AC; Eriksson E; Gyzander E; Medegard A; Risberg B
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(1):121-34. PubMed ID: 6177593
    [No Abstract]   [Full Text] [Related]  

  • 9. Severity of coronary artery disease and basal fibrinolysis.
    Small M; Lowe GD; Beattie JM; Hutton I; Lorimer AR; Forbes CD
    Haemostasis; 1987; 17(5):305-11. PubMed ID: 2444504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Components of the fibrinolytic system of Guerin's epithelioma].
    Zurawski P; Zagórska M; Grygoruk M; Worowski K
    Acta Haematol Pol; 1985; 16(3-4):151-7. PubMed ID: 3835771
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of the enzyme preparation longolytin on fibrinolysis in animals].
    Serebriakova TN; Andreenko GV; Tsymanovich SG; Maksimova RA; Sharkova TS
    Nauchnye Doki Vyss Shkoly Biol Nauki; 1985; (2):66-71. PubMed ID: 3157406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of epithelial tissue plasminogen activator as a thrombolytic agent in a rabbit model of venous thrombosis.
    Electricwala A; Emeis JJ; Atkinson T
    J Pharmacol Exp Ther; 1986 Jul; 238(1):254-8. PubMed ID: 2425075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis.
    Robbie LA; Booth NA; Croll AM; Bennett B
    Thromb Haemost; 1993 Aug; 70(2):301-6. PubMed ID: 8236139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current developments in fibrinolytic therapy].
    Rijken DC
    Ned Tijdschr Geneeskd; 1985 Sep; 129(37):1768-72. PubMed ID: 3934567
    [No Abstract]   [Full Text] [Related]  

  • 16. Synergistic fibrinolysis: combined effects of plasminogen activators and an antibody that inhibits alpha 2-antiplasmin.
    Reed GL; Matsueda GR; Haber E
    Proc Natl Acad Sci U S A; 1990 Feb; 87(3):1114-8. PubMed ID: 1689060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a synthetic carboxy-terminal peptide of alpha(2)-antiplasmin on urokinase-induced fibrinolysis.
    Lee KN; Jackson KW; McKee PA
    Thromb Res; 2002 Feb; 105(3):263-70. PubMed ID: 11927133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histidine-rich glycoprotein and alpha 2-plasmin inhibitor in inhibition of plasminogen binding to fibrin.
    Ichinose A; Mimuro J; Koide T; Aoki N
    Thromb Res; 1984 Feb; 33(4):401-7. PubMed ID: 6710439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbon monoxide-releasing molecule-2 decreases fibrinolysis in human plasma.
    Nielsen VG; Kirklin JK; George JF
    Blood Coagul Fibrinolysis; 2009 Sep; 20(6):448-55. PubMed ID: 19581800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two forms of alpha 2-antiplasmin: post-traumatic changes in the rat.
    Högstorp H; Carlin G
    Ups J Med Sci; 1987; 92(1):79-83. PubMed ID: 2438835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.